SpeechDx, supported by the ADDF’s Diagnostic Accelerator, invites industry, biotech and academic leaders to create a new class of digital biomarkers
SpeechDx speech and clinical data from each individual will be paired and, ultimately, harmonized across all clinical sites
NEW YORK, Oct. 23, 2023 /PRNewswire/ — The Alzheimer’s Drug Discovery Foundation’s (ADDF) Diagnostic Accelerator (DxA) today announced the launch of SpeechDx, the first longitudinal study aimed at creating the largest repository of speech and voice data to help accelerate the detection, diagnosis and monitoring of Alzheimer’s disease. Recorded voice samples from the study will be paired with clinical and biomarker data that can be leveraged by academic, biotech, and industry partners to develop algorithms for the creation of new speech biomarkers.
Scientific literature has shown subtle changes in speech and language patterns can indicate and predict cognitive decline associated with Alzheimer’s, but to-date, tools have struggled to systematically capture these alterations. Recent technological advancements in conjunction with the boom in artificial intelligence and machine learning have enabled us to record these difficult-to-detect changes, thus setting the ground for the use of speech and voice as a new class of digital biomarkers for Alzheimer’s.
“Speech is a complex cognitive process that contains important information about how your brain is functioning and scientific evidence shows us speech may hold the key to early, accurate, and non-invasive detection of Alzheimer’s disease,” says Howard Fillit, MD, Co-Founder and Chief Science Officer of the ADDF. “This study will help develop and validate voice-based biomarkers, expanding our existing arsenal of neuroimaging, peripheral blood, and digital biomarkers—all of which are crucial to delivering the right drugs to the right patients at the right time.”
SpeechDx is poised to develop a paired voice and clinical database that will provide the research community with harmonized data needed to generate speech-based diagnostic algorithms. These efforts will not only expand the existing portfolio of peripheral and digital biomarkers, but also further the DxA’s vision to accelerate the development of non-invasive and accessible biomarkers and diagnostic tools for the early detection of Alzheimer’s.
“To our knowledge, SpeechDx will comprise the largest-in-size, and longest-in-duration, curated repository of voice and clinical ground truth in dementia research,” said Lampros Kourtis, PhD, DxA SpeechDx Program Manager at Gates Ventures. “Our hope is that scientists can use this dataset to train, validate and benchmark algorithms that detect and monitor cognitive decline at early stages of disease development.”
This study will span a three-year period across five clinical sites in the U.S., Spain, and Australia, including Boston University, Emory University, Barcelona Brain Health Initiative, Barcelonaβeta Brain Research Center (BBRC), and the Ace Alzheimer Center Barcelona. The data will be collected from a diverse pool of 2,650 participants with full brain health spectrum from cognitively healthy to early Alzheimer’s, and in three languages including English, Spanish, and Catalan. Study participants will be given handheld tablets with the pre-installed SpeechDx app to capture their voice data.
The study sites and partners share a collective vision to create a gold-standard speech and language Alzheimer’s dataset that will be accessible by biotech, pharma, and research communities through the Alzheimer’s Disease Data Initiative‘s (ADDI) data and analysis sharing platform. The use of this warehouse of data will be fundamental for the development of new and renewable digital voice biomarkers.
“Machine learning algorithms are being integrated into every aspect of medical research, but the outputs are only as good as the data they are being built on,” remarks Niranjan Bose, PhD, Managing Director of Health & Life Sciences at Gates Ventures. “Implementation and development of the SpeechDx program will streamline the collection of high-quality speech data and ultimately complement the existing array of available biomarkers, including expanding the portfolio of digital tools used to predict and prevent the onset of the disease early on.”
Participants will be provided with a custom speech-collection app developed by the DxA which uses entirely open-source speech tasks. Additionally, each participant’s voice recording will be paired with clinical data and harmonized across all sites. This integration of clinical-digital data will serve as a ground point for machine learning, thus enabling higher accuracy. The collected data will be stored via the ADDI’s platform, which will function as a digital repository and contain approximately 2,584 hours of voice data to be used for the creation of algorithms for Alzheimer’s detection and monitoring.
For more information about the SpeechDx study visit the website here.
About the Alzheimer’s Drug Discovery Foundation (ADDF)
Founded in 1998 by Leonard A. and Ronald S. Lauder, the Alzheimer’s Drug Discovery Foundation is dedicated to rapidly accelerating the discovery of drugs to prevent, treat and cure Alzheimer’s disease. The ADDF is the only public charity solely focused on funding the development of drugs for Alzheimer’s, employing a venture philanthropy model to support research in academia and the biotech industry. The ADDF’s leadership and contributions to the field have played a pivotal role in bringing the first Alzheimer’s PET scan (Amyvid®) and blood test (PrecivityAD®) to market, as well as fueling the current robust and diverse drug pipeline. Through the generosity of its donors, the ADDF has awarded more than $270 million to fund over 730 Alzheimer’s drug development programs, biomarker programs and clinical trials in 19 countries. To learn more, please visit: http://www.alzdiscovery.org/.
About the Diagnostics Accelerator (DxA)
The Diagnostics Accelerator, created in July 2018, is a $100 million global research initiative from partners including ADDF Co-Founder Leonard A. Lauder, Bill Gates, Jeff Bezos, MacKenzie Scott, the Dolby family, the Charles and Helen Schwab Foundation, The Association for Frontotemporal Degeneration, among others, to develop novel biomarkers for the early detection of Alzheimer’s disease and related dementias.
This research initiative is dedicated to accelerating the development of affordable and accessible biomarkers to diagnose Alzheimer’s disease and related dementias and advance the clinical development of more targeted treatments. Through translational research awards and access to consulting support from industry experts, this program will challenge, assist, and fund the research community in both academia and industry to develop novel peripheral and digital biomarkers.
SOURCE Alzheimer’s Drug Discovery Foundation
